Resecting Colorectal Liver Metastases in Progressive Disease Improves Survival

Surgery for colorectal liver metastases after chemotherapy failure can offer survival benefits.

Patients with progressive disease underwent hepatectomy showed a 5-year overall survival rate of 42.7%.
This is lower than those with controlled disease (62.0% in complete/partial response and 55.5% in stable disease, p<0.001).
However, resected progressive disease patients had better survival (46.5%) than non-resected partial response patients (11.4%, p<0.001).
Preoperative carcinoembryonic antigen (CEA) ≥100 ng/ml and metachronous liver metastases are key risk factors for poor outcomes.

Consider surgical options cautiously in progressive disease cases.

Journal Article by Kobayashi K, Kishi Y (…) Kawai K et 10 al. in Ann Surg Oncol

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Ann Surg Oncol22 Oct 2026

Pancreatic cancer: occult spread in 1 in 4

In this prospective multicenter cohort, staging laparoscopy found occult metastases in 25% of imaging-M0 patients—including 20.6% with resectable disease—potentially sparing some patients a nonbeneficial resection.

BMC Surg22 Oct 2026

Robotic pancreatectomy tied to fewer complications

In an instrumental-variable analysis of 55,514 Medicare pancreatectomies, robotic surgery was associated with better outcomes than open surgery, but not laparoscopy.

J Gastrointest Surg21 Oct 2026

Primary closure after bile duct exploration: 0.4% leak

In this 743-patient single-center series, laparoscopic bile duct exploration achieved 95.6% stone clearance with a 0.4% bile-leak rate—reassuring results for surgeons considering T-tube-free closure.

All papers in HPB & Spleen →